2002-2013年美国成人他汀使用与支出的全国趋势
该回顾性纵向队列研究基于医疗支出面板调查数据库,分析2002-2013年美国40岁及以上成人他汀使用与费用趋势。
要点
- 他汀使用率十年间增长79.8%,但高危人群使用仍不充分。
- 仿制他汀使用比例从8.4%升至81.8%,显著降低自付费用。
- 女性、少数族裔及无保险者他汀使用显著较低。
核心结论
- 美国成人他汀使用大幅增加,但高危群体使用仍不理想。
- 总费用和自付费用均下降,进一步换用仿制他汀可带来更多节省。
研究设计与样本
- 回顾性纵向队列研究,使用2002-2013年医疗支出面板调查数据库。
主要发现
- 确诊ASCVD者他汀使用从49.8%升至58.1%,但不足三分之一为高强度剂量。
- 女性使用他汀的比值比为0.81(95%CI 0.79-0.85),少数族裔为0.65(95%CI 0.61-0.70),无保险者为0.33(95%CI 0.30-0.37)。
- 仿制他汀使用比例从8.4%升至81.8%。
关键数值与推荐
- 2012-2013年品牌他汀使用者占18.2%,却占总费用的55%。
临床怎么用
- 应关注女性、少数族裔和无保险等高危人群的他汀使用不足问题。
- 优先使用仿制他汀可降低患者自付费用和总支出。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Statins remain a mainstay in the prevention and treatment of atherosclerotic cardiovascular disease (ASCVD). OBJECTIVE: To detail the trends in use and total and out-of-pocket (OOP) expenditures associated with statins in a representative US adult population from 2002 to 2013. DESIGN, SETTING, AND PARTICIPANTS: This retrospective longitudinal cohort study was conducted from January 2002 to December 2013. Demographic, medical condition, and prescribed medicine information of adults 40 years and older between 2002 and 2013 were obtained from the Medical Expenditure Panel Survey database. MAIN OUTCOMES AND MEASURES: Estimated trends in statin use, total expenditure, and OOP share among the general adult population, those with established ASCVD, and those at risk for ASCVD. Costs were adjusted to 2013 US dollars using the Gross Domestic Product Index. RESULTS: From 2002 to 2013, more than 157 000 Medical Expenditure Panel Survey participants were eligible for the study (mean [SD] age, 57.7 [39.9] years; 52.1% female). Overall, statin use among US adults 40 years of age and older in the general population increased 79.8% from 21.8 million individuals (17.9%) in 2002-2003 (134 million prescriptions) to 39.2 million individuals (27.8%) in 2012-2013 (221 million prescriptions). Among those with established ASCVD, statin use was 49.8% and 58.1% in 2002-2003 and 2012-2013, respectively, and less than one-third were prescribed as a high-intensity dose. Across all subgroups, statin use was significantly lower in women (odds ratio, 0.81; 95% CI, 0.79-0.85), racial/ethnic minorities (odds ratio, 0.65; 95% CI, 0.61-0.70), and the uninsured (odds ratio, 0.33; 95% CI, 0.30-0.37). The proportion of generic statin use increased substantially, from 8.4% in 2002-2003 to 81.8% in 2012-2013. Gross domestic product-adjusted total cost for statins decreased from $17.2 billion (OOP cost, $7.6 billion) in 2002-2003 to $16.9 billion (OOP cost, $3.9 billion) in 2012-2013, and the mean annual OOP costs for patients decreased from $348 to $94. Brand-name statins were used by 18.2% of statin users, accounting for 55% of total costs in 2012-2013. CONCLUSION AND RELEVANCE: Statin use increased substantially in the last decade among US adults, although the uptake was suboptimal in high-risk groups. While total and OOP expenditures associated with statins decreased, further substitution of brand-name to generic statins may yield more savings.
引用
- Salami JA, Warraich H, Valero-Elizondo J, et al. National Trends in Statin Use and Expenditures in the US Adult Population From 2002 to 2013: Insights From the Medical Expenditure Panel Survey. JAMA Cardiol. 2017. PMID: 27842171. doi:10.1001/jamacardio.2016.4700
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。